Details for New Drug Application (NDA): 208711
✉ Email this page to a colleague
NDA 208711 describes EGATEN, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. Additional details are available on the EGATEN profile page.
The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the triclabendazole profile page.
The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the triclabendazole profile page.
Summary for 208711
| Tradename: | EGATEN |
| Applicant: | Novartis |
| Ingredient: | triclabendazole |
| Patents: | 0 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208711
Generic Entry Date for 208711*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 208711
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| EGATEN | triclabendazole | TABLET;ORAL | 208711 | NDA | Novartis Pharmaceuticals Corporation | 0078-0937 | 0078-0937-91 | 4 TABLET in 1 BLISTER PACK (0078-0937-91) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Feb 13, 2019 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Feb 13, 2026 | ||||||||
| Regulatory Exclusivity Use: | INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER | ||||||||
| Regulatory Exclusivity Expiration: | Feb 13, 2024 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Complete Access Available with Subscription
